Group 1 - BrainsWay Ltd. will report its fourth quarter and full year 2024 financial results on March 11, 2025, before the U.S. financial markets open [1] - A conference call and webcast will be held at 8:30 AM Eastern Time to discuss the results and provide an update on business operations [1][2] - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [3] Group 2 - The company has obtained three FDA-cleared indications for its TMS technology, which include major depressive disorder, obsessive-compulsive disorder, and smoking addiction [3] - BrainsWay is committed to advancing neuroscience and increasing global awareness and access to Deep TMS [3] - Additional clinical trials for Deep TMS are currently underway in various psychiatric, neurological, and addiction disorders [3]

Company Performance - Brainsway Ltd. Sponsored ADR (BWAY) shares have increased by 18.2% over the past month, reaching a new 52-week high of $11.09 [1] - Year-to-date, the stock has gained 17.2%, outperforming the Zacks Medical sector, which declined by 3.2%, and the Zacks Medical - Products industry, which returned 17.1% [1] Earnings and Revenue - Brainsway has consistently exceeded earnings expectations, reporting an EPS of $0.04 against a consensus estimate of $0.01 in its last earnings report on November 12, 2024, and beating revenue estimates by 4.33% [2] - For the current fiscal year, Brainsway is projected to earn $0.16 per share on revenues of $40.41 million, with a year-over-year earnings growth of 93.75% [3] - The next fiscal year forecasts earnings of $0.21 per share on revenues of $46.38 million, representing a year-over-year change of 14.78% [3] Valuation Metrics - Brainsway has a Value Score of D, a Growth Score of A, and a Momentum Score of C, resulting in a VGM Score of B [6] - The stock trades at 71.3X current fiscal year EPS estimates, significantly higher than the peer industry average of 18.7X, while on a trailing cash flow basis, it trades at 5X compared to the peer group's average of 11.5X [6] Zacks Rank - Brainsway holds a Zacks Rank of 1 (Strong Buy), supported by favorable earnings estimate revisions from analysts [7] - The combination of a Strong Buy rating and a VGM Score of B suggests potential for further stock price appreciation in the near term [8] Industry Comparison - The Medical - Products industry is performing well, ranking in the top 38% of all industries, indicating positive market conditions for both Brainsway and its peers [11] - ResMed Inc. (RMD), a competitor, has a Zacks Rank of 2 (Buy) and has also shown strong earnings performance, with a projected EPS of $9.35 on revenues of $5.1 billion for the current fiscal year [9][10]

Company Overview - Brainsway Ltd. (BWAY) shares increased by 8% to close at $11.05, supported by high trading volume, and have gained 11.8% over the past four weeks [1] - The company reported a 26% year-over-year revenue growth in Q3, alongside positive net income, which has led to optimistic investor sentiment regarding its growth prospects [2] Financial Performance - BWAY is expected to report quarterly earnings of $0.03 per share, reflecting a year-over-year increase of 200%, with revenues projected at $10.84 million, up 20% from the previous year [3] - The consensus EPS estimate for BWAY has been revised 250% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Market Position - BWAY holds a Zacks Rank of 1 (Strong Buy), indicating strong market confidence in the stock [4] - In the same medical products industry, AtriCure (ATRC) has also shown positive performance, with a 3% increase in its stock price and a 26.1% return over the past month [4]

Core Viewpoint - Brainsway Ltd. Sponsored ADR (BWAY) shows a significant improvement in earnings outlook, making it an attractive investment option as analysts continue to raise earnings estimates for the company [1][3]. Current-Quarter Estimate Revisions - The company is projected to earn $0.03 per share for the current quarter, reflecting a year-over-year increase of +200% [4]. - Over the past 30 days, there has been one upward revision in estimates with no negative revisions, leading to a 250% increase in the Zacks Consensus Estimate [4]. Current-Year Estimate Revisions - For the full year, Brainsway is expected to earn $0.08 per share, indicating a year-over-year change of +130.77% [5]. - The trend for current-year estimates is positive, with one estimate moving higher and no negative revisions, resulting in a 67.57% increase in the consensus estimate [5]. Favorable Zacks Rank - The positive estimate revisions have earned Brainsway a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance [6]. - Research indicates that stocks with Zacks Rank 1 and 2 significantly outperform the S&P 500 [6]. Bottom Line - Strong estimate revisions have led to a 5.9% increase in Brainsway's stock over the past four weeks, suggesting further upside potential [7].

Group 1: Stock Performance and Price Targets - Brainsway Ltd. Sponsored ADR (BWAY) closed at $9.89, with a 5.9% gain over the past four weeks, and a mean price target of $13.73 indicating a 38.8% upside potential [1] - The average price targets range from a low of $12.50 to a high of $16, with a standard deviation of $1.56, suggesting a 26.4% increase at the lowest estimate and a 61.8% increase at the highest [2] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [7] Group 2: Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism about BWAY's earnings prospects, with strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [9] - The Zacks Consensus Estimate for the current year has increased by 67.6% due to one estimate moving higher over the last 30 days without any negative revisions [10] - BWAY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [11] Group 3: Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [6] - While price targets are commonly sought after, they can mislead investors more often than guide them accurately [5] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [8]

Group 1: Company Highlights - Brainsway (BWAY) is a commercial stage medical device company focused on non-invasive neuromodulation products, with a 60% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Grupo Televisa (TV) is the largest media company in the Spanish-speaking world, experiencing a 22.2% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - ICU Medical (ICUI) develops innovative medical devices for vascular therapy, oncology, and critical care, with a 7.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3] - Sally Beauty (SBH) is an international specialty retailer of professional beauty supplies, seeing a 6.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3] - PHINIA Inc. (PHIN) provides premium solutions and components in manufacturing, with a 5.2% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [4] Group 2: Investment Opportunities - The stocks mentioned have been added to the Zacks Rank 1 (Strong Buy) List, indicating strong potential for investment [1][2][3][4]

BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced recent positive pilot data from an independent, third-party study conducted at Stanford University evaluating an accelerated protocol using the Company’s Deep Transcranial Magnetic Stimulation (TMS) technology to treat alcohol use disorder (AUD) patients. The outcomes were reported in ...

BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of positive feasibility clinical data evaluating the analgesic effects of deep transcranial magnetic stimulation (Deep TMS™) in patients with peripheral neuropathic pain. The results were published in the Neuromodulation journal, in a peer ...

BrainsWay Ltd. (NASDAQ:BWAY) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call Participants Steven Lichtman - Oppenheimer Jeff Cohen - Ladenburg Thalmann & Company Operator Good day, and welcome to the BrainsWay Third Quarter 2024 Earnings Conference Call. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference over to Brian Ritchie of Life ...

Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported third quarter 2024 financial results and provided an operatio ...